|
|
|
European Biopharmaceutical Review
|
The current advances in immunoncology are constantly rewriting the landscape of this field and changing the standard care of many types of cancer. Immunotherapy harnesses the immune system to fight cancer, and recent research has focused on teasing tumour cells out from their protective microenvironments by exposing them to the patient’s immune response, which has led to the development of new immunotherapies.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
Dr Katie Chapple is a Scientist at Sartorius Stedim Biotech, working within the technical development team. She joined the company in 2016, following the successful completion of a PhD in neuroimmunology at University of Glasgow, UK, which focused on the autoantibody response in multiple sclerosis. Katie’s current position builds on her already-rounded knowledge of assay development, with an emphasis on using complex immunoassays to better understand treatment responses. Her role focuses on flow cytometry assay development and using this platform as a powerful tool to characterise mAb’s MOA.
Andrea Gomez-Donart is an Associate Scientist in the cell analytics branch of Sartorius Stedim Biotech, working within the R&D assay development team. She joined Sartorius in 2018 after 18 years of research in the applied toxicology field, testing preclinical drugs for efficacy, toxicity, and biodistribution. Andrea is currently an active member of the assay development group, designing assay kits to be used on the IntelliCyt iQue® Screener Plus highthroughput flow cytometry platform.
|
|
|
Dr Katie Chapple |
|
|
|
|
Andrea Gomez-Donart |
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
GSK Completes Acquisition of Sierra Oncology
London, UK, 1 July, 2022: GSK plc (LSE/NYSE: GSK) today announced
it has completed the acquisition of Sierra Oncology, Inc. (Sierra
Oncology), a California-based biopharmaceutical company focused on
targeted therapies for the treatment of rare forms of cancer. The
acquisition was approved by Sierra Oncology's shareholders on 29 June
2022.
More info >> |
|
 |
White Papers |
 |
|
Quality By Design
Biopharma Group
Quality by Design (QbD) is a systematic approach to development that begins with the defined objectives and emphasizes science and quality risk management in order to achieve those goals. QbD ensures that the quality of the product is built into production processes from the outset, rather than being tested after development has already commenced.
More info >> |
|
|
